SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

QR Code

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Lahore, from Mar 2018 to Oct 201...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Arif Qayyum Khan, Hala Mansoor, Samina Fida, Saba Saif, Javed Iqbal, Muhammad Siddique
Format:	article
Langue:	EN
Publié:	Army Medical College Rawalpindi 2021
Sujets:	hepatitis c sustained virological response sofosbuvir velpatasvir Medicine R Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/2841f49f314e4c478be8efc7acad314a
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
par: Mohamed G. Mohamed, et autres
Publié: (2021)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
par: Pol S, et autres
Publié: (2016)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
par: Arif Qayyum Khan, et autres
Publié: (2020)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
par: Arif Qayyum Khan, et autres
Publié: (2020)

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
par: Kutala BK, et autres
Publié: (2017)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
par: María E. Cárdaba-García, et autres
Publié: (2021)

ENHANCEMENT SPECTRAL RESOLUTION FOR THE PREDICTION AMOUNT OF SOFOSBUVIR AND LEDIPASVIR USING LEAST SQUARES SUPPORT VECTOR MACHINE AND ARTIFICIAL NEURAL NETWORKS IN PHARMACEUTICAL FORMULATION
par: Safakhoo,Negin, et autres
Publié: (2019)

Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
par: David E Bloom, et autres
Publié: (2021)

Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C
par: Tseng CW, et autres
Publié: (2016)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
par: Irina RUSU, et autres
Publié: (2020)

Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
par: Ng KJ, et autres
Publié: (2016)

Possible acute rejection associated with the use of the new antihepatitis C virus medications
par: Khaled Ar Karkout, et autres
Publié: (2019)

Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages
par: Caroline Gravel, et autres
Publié: (2021)

Prestimulation of CD2 confers resistance to HIV-1 latent infection in blood resting CD4 T cells
par: Sijia He, et autres
Publié: (2021)

IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells
par: Tomas Raul Wiche Salinas, et autres
Publié: (2021)

Influenza A induces lactate formation to inhibit type I IFN in primary human airway epithelium
par: Jacob Thyrsted, et autres
Publié: (2021)

Merkel cell polyomavirus T-antigens regulate DICER1 mRNA stability and translation through HSC70
par: Jiwei Gao, et autres
Publié: (2021)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
par: Ibrahim Anam Ezzelregal, et autres
Publié: (2020)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
par: Takuya Tada, et autres
Publié: (2021)

A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
par: Miyasaka A, et autres
Publié: (2021)

Snake Deltavirus Utilizes Envelope Proteins of Different Viruses To Generate Infectious Particles
par: Leonora Szirovicza, et autres
Publié: (2020)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
par: Naylor PH, et autres
Publié: (2017)

Identification of a Novel Deltavirus in Boa Constrictors
par: Udo Hetzel, et autres
Publié: (2019)

Virology journal
Publié: (2004)

The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells
par: Andrew D. Huber, et autres
Publié: (2018)

The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
par: Thushan I. de Silva, et autres
Publié: (2021)

Archives of virology

Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants
par: Eva Lopez, et autres
Publié: (2021)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
par: Sundaram V, et autres
Publié: (2016)

Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
par: Abdulla MA, et autres
Publié: (2017)

Advances in virology

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
par: Bernstein D, et autres
Publié: (2019)

Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus
par: Estefania Fernandez, et autres
Publié: (2018)

Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern
par: Qian Wang, et autres
Publié: (2021)

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
par: Caroline Schmidbauer, et autres
Publié: (2021)

Hepatitis research and treatment

Prevalencia de los Virus de Hepatitis en las Hepatitis Agudas en Niños
par: Zacarías S,José, et autres
Publié: (1983)

SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera
par: Alona Kuzmina, et autres
Publié: (2021)